Scarica l'app Stockscreener
6.42
5.84%
0.33
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALGS Giù?
Forum
Previsione
Precedente Chiudi:
$6.09
Aprire:
$6.1
Volume 24 ore:
33,305
Relative Volume:
0.20
Capitalizzazione di mercato:
$38.80M
Reddito:
$2.19M
Utile/perdita netta:
$-24.19M
Rapporto P/E:
-0.7464
EPS:
-8.6017
Flusso di cassa netto:
$-82.94M
1 W Prestazione:
+0.25%
1M Prestazione:
-19.12%
6M Prestazione:
-10.60%
1 anno Prestazione:
+15.11%
Intervallo 1D:
$6.06
$6.4459
Intervallo di 1 settimana:
$5.91
$6.58
Portata 52W:
$4.20
$13.69
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Nome
Aligos Therapeutics Inc
Settore
Industria
Telefono
(800) 466-6059
Indirizzo
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
6.2701 | 37.69M | 2.19M | -24.19M | -82.94M | -8.6017 |
VRTX
Vertex Pharmaceuticals Inc
|
426.26 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
707.48 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
803.16 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.88 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
299.52 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-19 | Ripresa | Jefferies | Buy |
| 2025-08-18 | Ripresa | H.C. Wainwright | Buy |
| 2024-08-19 | Iniziato | H.C. Wainwright | Buy |
| 2023-01-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-01-06 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-01-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-09 | Iniziato | SVB Leerink | Outperform |
| 2021-05-17 | Ripresa | Piper Sandler | Overweight |
| 2020-11-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Iniziato | JP Morgan | Overweight |
| 2020-11-10 | Iniziato | Jefferies | Buy |
| 2020-11-10 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Aligos Therapeutics Inc Borsa (ALGS) Ultime notizie
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026 - Investing News Network
Biotech Aligos will post first-quarter results after markets close May 7 - Stock Titan
[ARS] Aligos Therapeutics, Inc. SEC Filing - Stock Titan
Aligos Therapeutics says China pact puts HBV drug in focus amid trial updates - MSN
Aligos Therapeutics (Nasdaq: ALGS) details ESPP, auditor and pay votes - Stock Titan
Aligos’ licensing deal in China broadens trial scope, secures immediate $25m - MLex
Is Aligos (ALGS) overbought or oversold? (Drifts Higher) 2026-04-27Retail Flow - Newser
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
This micro cap biotech stock is tracking its biggest intraday gains in 11 months – here’s why a China deal has retail buzzing - MSN
(ALGS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Aligos Therapeutics (ALGS) Gets a Buy from H.C. Wainwright - The Globe and Mail
New Aligos hires get stock options for 10,700 shares under Nasdaq rule - Stock Titan
Aligos Therapeutics jumps on China licensing agreement - MSN
Aligos (ALGS) Stock: Why Margin Improvement (Institutional Demand) 2026-04-22Short Term Trading - Cổng thông tin điện tử tỉnh Tây Ninh
Aligos Therapeutics Licenses Hepatitis B Drug Rights to Amoytop - TipRanks
Aligos Therapeutics (NASDAQ: ALGS) signs Hep B deal with up to $420M milestones - Stock Titan
Aligos (ALGS) Stock Volume Confirmation (Wavering) 2026-04-20Earnings Season - Cổng thông tin điện tử tỉnh Lào Cai
10 Health Care Stocks Moving In Friday's Intraday Session - Sahm
H.C. Wainwright reiterates Aligos stock rating on China deal - Investing.com UK
Aligos strikes license deal with Amoytop for HBV therapy development - The Pharma Letter
This drugmaker was about to run out of cash, but a Chinese partner came to the rescue - The Business Journals
H.C. Wainwright reiterates Aligos stock rating on China deal By Investing.com - Investing.com Canada
Aligos and Xiamen Amoytop sign deal for HBV therapy - Yahoo Finance
Aligos licenses hepatitis B drug to Amoytop for $25m upfront - Investing.com India
Aligos Therapeutics Says China Pact Puts HBV Drug In Focus Amid Trial Updates - Sahm
Jefferies reiterates Aligos Therapeutics stock rating on China deal By Investing.com - Investing.com South Africa
Jefferies reiterates Aligos Therapeutics stock rating on China deal - Investing.com
Aligos licenses hepatitis B drug to Amoytop for $25m upfront By Investing.com - Investing.com South Africa
Aligos Therapeutics Licenses Hepatitis B Drug to Xiamen Amoytop for Greater China - National Today
Aligos Therapeutics (ALGS) Secures Licensing Deal for Hepatitis B Treatment - GuruFocus
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Aligos Therapeutics stock surges on China licensing deal - Investing.com
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection - Investing News Network
Aligos Therapeutics stock surges on China licensing deal By Investing.com - Investing.com Canada
Aligos Therapeutics jumps 22% on Greater China deal for Hepatitis B drug (ALGS:NASDAQ) - Seeking Alpha
More than 90 million live with HBV in Greater China; Aligos signs deal - Stock Titan
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Sahm
Hepatitis B: Updates from Aligos Therapeutics, Arbutus Biopharma Corporation and Precision BioSciences - European AIDS Treatment Group
Aligos Therapeutics Inc Azioni (ALGS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.83%
2.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):